How should I manage constipation lasting two weeks in a patient taking tirzepatide (Zepbound)?

Management of Tirzepatide-Induced Constipation

Start with bisacodyl 10-15 mg daily and polyethylene glycol (PEG) 17 g daily, titrating upward as needed, while ensuring the patient maintains adequate hydration and continues tirzepatide therapy. 1, 2

Understanding the Problem

Constipation is a common, dose-dependent adverse effect of tirzepatide (Zepbound), occurring in approximately 2.5% of patients in clinical trials 3. The most recent 2025 AACE consensus statement confirms that gastrointestinal side effects, including constipation, are the most common adverse events with GLP-1 receptor agonist-based medications like tirzepatide, typically occurring during dose escalation 4.

Initial Management Approach

First-Line Therapy

Immediately initiate a stimulant laxative combined with an osmotic agent:

• Bisacodyl 10-15 mg daily (can increase to three times daily if needed) 1
• Polyethylene glycol (PEG) 17 g daily (no clear maximum dose; titrate to response) 2
• Goal: One non-forced bowel movement every 1-2 days 1

The 2023 AGA-ACG guideline on chronic constipation supports PEG as a first-line agent with durable response over 6 months, though common side effects include bloating and cramping 2. The 2016 NCCN palliative care guidelines emphasize that bisacodyl should be titrated aggressively with this goal in mind 1.

Essential Supportive Measures

• Increase fluid intake significantly 1
• Encourage physical activity if feasible 1
• Avoid adding fiber supplements (compounds like Metamucil are unlikely to control medication-induced constipation and may worsen symptoms) 5

Critical Assessment Steps

Before escalating therapy, rule out mechanical complications:

• Check for fecal impaction (especially if any diarrhea is present—this may represent overflow) 1
• Rule out bowel obstruction with physical exam and consider abdominal imaging if symptoms are severe 1, 6
• Recent case reports document rare but serious complications including small bowel obstruction with tirzepatide 6, 7

Escalation Strategy if Constipation Persists

If the patient has no bowel movement after 3-4 days despite initial therapy:

Second-Line Options (Add One or More)

• Lactulose 30-60 mL twice to four times daily 1, 2
• Magnesium hydroxide 30-60 mL daily to twice daily 1
• Magnesium citrate 8 oz daily 1
• Bisacodyl suppository (10 mg) once to twice daily rectally 1

Third-Line: Prokinetic Agent

If gastroparesis or severe dysmotility is suspected:

• Metoclopramide 10-20 mg PO four times daily 1

Novel Targeted Therapy

A 2026 case report demonstrates that elobixibat (an ileal bile acid transporter inhibitor) 5-10 mg daily may provide effective rescue therapy when conventional laxatives fail, allowing continuation of tirzepatide 8. This represents a mechanism-based approach specifically targeting incretin-induced motility deficits. Start at 10 mg daily before dinner; reduce to 5 mg if loose stools develop 8.

Important Clinical Considerations

Do NOT Discontinue Tirzepatide Prematurely

The 2026 SURMOUNT-MAINTAIN trial demonstrates that continuing tirzepatide long-term maintains weight reduction (-21.9% at 112 weeks with maximum tolerated dose) 9. Discontinuation leads to significant weight regain 9. Aggressive constipation management should be prioritized over medication discontinuation.

Dose Reduction Alternative

If constipation remains intolerable despite maximal laxative therapy, consider reducing tirzepatide to 5 mg weekly rather than complete discontinuation. The SURMOUNT-MAINTAIN trial showed that dose reduction to 5 mg still maintained -16.6% weight loss, significantly better than placebo 9.

Timing Matters

The 2025 AACE guidelines emphasize that GI side effects occur most commonly during dose escalation 4. If the patient recently increased their tirzepatide dose, consider holding at the current dose rather than further escalation until constipation is controlled.

Red Flags Requiring Urgent Evaluation

• Severe abdominal pain with distension (possible obstruction) 6
• Vomiting with inability to pass gas (possible obstruction) 6
• No bowel movement for >7 days despite aggressive therapy 1
• Syncope or severe dehydration 6

Common Pitfalls to Avoid

1. Adding fiber supplements - These are ineffective for medication-induced constipation and may worsen bloating 5
2. Using stool softeners alone - Docusate without a stimulant laxative is insufficient 1
3. Discontinuing tirzepatide too quickly - Aggressive laxative management should be attempted first 8, 9
4. Inadequate hydration - Osmotic laxatives require adequate fluid intake to work effectively 1, 2

Practical Algorithm Summary

1. Week 1-2: Bisacodyl 10-15 mg daily + PEG 17 g daily + increase fluids
2. If no improvement by day 3-4: Add lactulose 30-60 mL BID or magnesium hydroxide 30-60 mL daily
3. If still constipated: Add bisacodyl suppository + consider metoclopramide 10-20 mg QID
4. If refractory: Consider elobixibat 5-10 mg daily OR reduce tirzepatide dose to 5 mg weekly
5. Throughout: Rule out impaction/obstruction if symptoms worsen